Sign Out
Pregnancy: Cyproterone acetate+ Ethinylestradiol (Faye) is not indicated during pregnancy. If pregnancy occurs during treatment with Cyproterone acetate + Ethinylestradiol (Faye), further intake must be stopped (see Toxicology: Preclinical safety data under Actions).
Lactation: The administration of Cyproterone acetate + Ethinylestradiol (Faye) is contraindicated during lactation. Cyproterone acetate is transferred into the milk of lactating women. About 0.2% of the maternal dose will reach the newborn via milk corresponding to a dose of about 1 μg/kg. 0.02% of the daily maternal dose of ethinylestradiol could be transferred to the newborn via milk during established lactation.
Continue with Google